Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 2/2015

01.04.2015 | Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

The Benefits of Revascularization in Chronic Heart Failure

verfasst von: Sothinathan Gurunathan, Asrar Ahmed, Roxy Senior

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Recent efforts have reduced the mortality from coronary artery disease (CAD), with the consequent increase in heart failure with reduced left ventricular function, referred to as ischaemic cardiomyopathy (ICM). As ischemic left ventricular (LV) dysfunction may be partially or completely reversible by revascularization in the presence of viable myocardium, the assessment of myocardial viability is central to the management of ICM. Decades of observational analyses have provided positive evidence for the role of revascularization in hibernating myocardium in improving survival. However, recently the Surgical Treatment for Ischaemic Heart Failure (STICH) trial has challenged this notion, highlighting the noninferiority of optimal medical therapy (OMT) over revascularization and OMT. In this review, we discuss noninvasive imaging modalities to assess myocardial viability and the impact of myocardial viability on revascularization. We critically appraise the STICH trial and suggest an algorithm for viability testing before revascularization in patients with ICM and significant LV dysfunction.
Literatur
1.
Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–63.CrossRefPubMed
2.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.CrossRefPubMed
3.
Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13:227–33.CrossRefPubMed
4.
Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(20):2002–12.
5.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–16.CrossRefPubMedCentralPubMed
6.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.CrossRefPubMedCentralPubMed
7.
Nihoyannopoulos P, Vanoverschelde JL. Myocardial ischaemia and viability: the pivotal role of echocardiography. Eur Heart J. 2011;32:810–9.CrossRefPubMed
8.
Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E. Imaging in the management of ischemic cardiomyopathy: special focus on magnetic resonance. J Am Coll Cardiol. 2012;59:359–70.CrossRefPubMed
9.
Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31:2984–95.CrossRefPubMed
10.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.CrossRefPubMed
11.
Schinkel AF, Bax JJ, Boersma E, Elhendy A, Vourvouri EC, Roelandt JR, et al. Assessment of residual myocardial viability in regions with chronic electrocardiographic Q-wave infarction. Am Heart J. 2002;144:865–9.CrossRefPubMed
12.
Bax JJ, Schinkel AF, Boersma E, Elhendy A, Rizzello V, Maat A, et al. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis. Circulation. 2004;110:II18–22.PubMed
13.
Schinkel AF, Poldermans D, Rizzello V, Vanoverschelde JL, Elhendy A, Boersma E, et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J Thorac Cardiovasc Surg. 2004;127:385–90.CrossRefPubMed
14.
Picano E, Sicari R, Landi P, Cortigiani L, Bigi R, Coletta C, et al. Prognostic value of myocardial viability in medically treated patients with global left ventricular dysfunction early after an acute uncomplicated myocardial infarction: a dobutamine stress echocardiographic study. Circulation. 1998;98(11):1078–84.CrossRefPubMed
15.
Rizzello V, Poldermans D, Schinkel AF, Biagini E, Boersma E, Elhendy A, et al. Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic cardiomyopathy undergoing coronary revascularisation. Heart. 2006;92:239–44.CrossRefPubMedCentralPubMed
16.•
Ro¨sner A, Avenarius D, Malm S, et al. Persistent dysfunction of viable myocardium after revascularization in chronic ischaemic heart disease: implications for dobutamine stress echocardiography with longitudinal systolic strain and strain rate measurements. Eur Heart J Cardiovasc Imaging. 2012;13:745–55. In this study, tissue Doppler imaging was performed during rest and LDD echocardiography in patients pre- and post-coronary artery bypass grafting. Increased longitudinal systolic strain with LDD predicted regional recovery in longitudinal function. In patients with no or minimal increase in strain, there was low likelihood of functional recovery after CABG. CrossRef
17.
Hickman M, Chelliah R, Burden L, Senior R. Resting myocardial blood flow, coronary flow reserve, and contractile reserve in hibernating myocardium: implications for using resting myocardial contrast echocardiography vs. dobutamine echocardiography for the detection of hibernating myocardium. Eur J Echocardiogr. 2010;11(9):756–62. doi:10.​1093/​ejechocard/​jeq062. Epub 2010 May 20.CrossRefPubMed
18.
Chelliah RK, Hickman M, Kinsey C, Burden L, Senior R. Myocardial contrast echocardiography versus single proton emission computed tomography for assessment of hibernating myocardium in ischaemic cardiomyopathy: preliminary qualitative and quantitative results. J Am Soc Echocardiogr. 2010;23(8):840–7.CrossRefPubMed
19.
Dwivedi G, Janardhanan R, Hayat SA, Swinburn JM, Senior R. Prognostic value of myocardial viability detected by myocardial contrast echocardiography early after acute myocardial infarction. J Am Coll Cardiol. 2007;50(4):327–34.CrossRefPubMed
20.
Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol. 1997;30(6):1451–60.CrossRefPubMed
21.
Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375–410.CrossRefPubMed
22.••
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6:363–72. This observational analysis evaluated the relative impact of PET-FDG-identified ischemic, hibernating, and scarred myocardium on potential survival benefits of revascularization in 648 patients with ICM. The study demonstrated survival benefits of the revascularization therapy in the presence of hibernating but not ischemic myocardium, when the extent of viability exceeded 10% of the LV myocardium. The risk of death with medical therapy increased proportionally with the amount of hibernating myocardium over the threshold of 10 %. CrossRefPubMed
23.
Baer FM, Theissen P, Schneider CA, Voth E, Sechtem U, Schicha H, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol. 1998;31(5):1040–8.CrossRefPubMed
24.
Abraham JL, Higgins CB, Newell JD. Uptake of iodinated contrast material in ischemic myocardium as an indicator of loss of cellular membrane integrity. Am J Pathol. 1980;101:319–30.PubMedCentralPubMed
25.
McNamara MT, Higgins CB, Ehman RL, Revel D, Sievers R, Brasch RC. Acute myocardial ischemia: magnetic resonance contrast enhancement with gadolinium-DTPA. Radiology. 1984;153:157–63.CrossRefPubMed
26.
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53.CrossRefPubMed
27.
Shah DJ, Kim HW, James O, Parker M, Wu E, Bonow RO, et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA. 2013;309(9):909–18.CrossRefPubMedCentralPubMed
28.•
Gerber BL, Rousseau MF, Ahn SA, le Polain de Waroux JB, Pouleur AC, Phlips T et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol. 2012;59(9):825–35. This observational study found benefit in revascularization, over OMT, in patients with ICM and viable myocardium as assessed by LGE-CMR. In patients with nonviable myocardium, treatment allocation did not affect outcomes.
29.•
Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc Imaging. 2012;5(5):494–508. This meta-analysis compared three CMR techniques used to assess myocardial viability in 698 patients with LV dysfunction secondary to CAD. LGE-CMR afforded the highest sensitivity for the prediction of improvement in LV function after revascularization. LDD-CMR had the lowest sensitivity but highest specificity compared to other CMR techniques. CrossRefPubMed
30.
Wellnhofer E, Olariu A, Klein C, Grafe M, Wahl A, Fleck E, et al. Magnetic resonance low-dose dobutamine test is superior to scar quantification for the prediction of functional recovery. Circulation. 2004;109:2172–4.CrossRefPubMed
31.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8.CrossRefPubMed
32.
Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O’Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J. 2003;146(4):621–7.CrossRefPubMed
33.
34.
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–17.CrossRefPubMedCentralPubMed
35.
Buckberg GD, Athanasuleas CL, Wechsler AS, Beyersdorf F, Conte JV, Strobeck JE. The STICH trial unravelled. Eur J Heart Fail. 2010;12:1024–7.CrossRefPubMed
36.
Fang JC. Underestimating medical therapy for coronary disease … again. N Engl J Med. 2011;364:1671–3.CrossRefPubMed
37.
Oh JK, Pellikka PA, Panza JA, Biernat J, Attisano T, Manahan BG, et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012;25:327–36.CrossRefPubMedCentralPubMed
38.
Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol. 2005;46:567–74.CrossRefPubMed
39.
Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2013;61(18):1860–70.
40.
Shah BN, Khattar RS, Senior R. The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era. Eur Heart J. 2013;34:1323–34.CrossRefPubMed
41.
Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS guidelines on myocardial revascularisation: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.
42.
O’Meara E, Mielniczuk LM, Wells GA, et al. Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE-HF Project 1-A: study protocol for a randomized controlled trial. Trials. 2013;14:218.CrossRefPubMedCentralPubMed
Metadaten
Titel
The Benefits of Revascularization in Chronic Heart Failure
verfasst von
Sothinathan Gurunathan
Asrar Ahmed
Roxy Senior
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2015
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-014-0245-1

Weitere Artikel der Ausgabe 2/2015

Current Heart Failure Reports 2/2015 Zur Ausgabe

Management of Heart Failure (TE Meyer, Section Editor)

Altered Breathing Syndrome in Heart Failure: Newer Insights and Treatment Options

Self-Care and Health Outcomes (T Jaarsma, Section Editor)

Can Cognitive Behaviour Therapy Be Beneficial for Heart Failure Patients?

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Current Practice in Patient Selecting for Long-Term Mechanical Circulatory Support

Management of Heart Failure (TE Meyer, Section Editor)

Tricuspid Valve Incompetence Following Implantation of Ventricular Leads

Epidemiology of Heart Failure (JE Ho, Section Editor)

Heart Failure in Women

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section Editor)

Pathophysiology of Sepsis-Related Cardiac Dysfunction: Driven by Inflammation, Energy Mismanagement, or Both?

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise